Cerus Raises Revenue Guidance on Strong IFC Demand and Platelet Growth
Event summary
- Cerus reported Q1 2026 revenue of $59.9M, up 23% YoY, driven by a 24% increase in product revenue to $53.7M.
- INTERCEPT Fibrinogen Complex (IFC) demand surged ~120% YoY, with U.S. sales rising from $3.0M to $5.7M.
- Signed a four-year supply agreement with EFS for INTERCEPT Blood System and INT200 device.
- CEO transition: Vivek Jayaraman to replace William 'Obi' Greenman as CEO on July 1, 2026.
The big picture
Cerus' strong Q1 performance underscores the growing adoption of pathogen reduction technologies in blood supply management. The IFC demand surge and platelet franchise strength signal a shift toward higher-margin therapeutic applications, while regulatory catalysts could unlock further market expansion. The leadership transition introduces governance dynamics to monitor amid these strategic inflection points.
What we're watching
- Regulatory Milestones
- The pace at which INTERCEPT RBC gains European approval and the U.S. RedeS Phase 3 readout could reshape Cerus' growth trajectory.
- Execution Risk
- Whether Cerus can sustain its 10-12% revenue growth guidance amid inflationary pressures and foreign exchange volatility.
- Leadership Transition
- How Vivek Jayaraman's CEO tenure will impact strategic priorities, particularly the U.S. PMA submission for INT200.
Related topics